Fatal gastrointestinal hemorrhage after a single dose of dabigatran

Clinical Toxicology

Volumn 50, Issue 7, 2012, Pages 571-573

  Kernan, Leah ^a   Ito, Satoru ^b   Shirazi, Farshad ^b   Boesen, Keith ^b  

^a U S ARMY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Anticoagulation; Gastric ulcer; Gastrointestinal hemorrhage; Pradaxa; Renal insufficiency

Indexed keywords

ADRENALIN; CREATININE; DABIGATRAN; DABIGATRAN ETEXILATE; ERYTHROMYCIN; ESOMEPRAZOLE; FRESH FROZEN PLASMA; HEMOGLOBIN; NORADRENALIN; VASOPRESSIN; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD PRESSURE; CASE REPORT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSIS; DRUG FATALITY; EMERGENCY WARD; ERYTHROCYTE CONCENTRATE; EXTUBATION; FECES; FLUID RESUSCITATION; GASTRIC ULCER BLEEDING; GASTROINTESTINAL ENDOSCOPY; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MALE; RECTUM HEMORRHAGE; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION; UREA NITROGEN BLOOD LEVEL; VITAL SIGN;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; FATAL OUTCOME; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE;

EID: 84865045736     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2012.705290     Document Type: Article

References (10)

1. Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fi brillation. Food and Drug Administration News Release. 2010 Oct 19. Available at http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm230241.htm.Accessed 2011 Nov 4.
2. Product Information: PRADAXA(R) oral capsules, dabigatran etexilate mesylate oral capsules. Boehringer Ingelheim Pharmaceuticals, Inc.
3. Palladino M, Thomson L, Swift B, Merli GJ. Implementing the new oral anticoagulants into the hospital formulary. Am J Hematol 2012; 87:S127-S132.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med 2009; 361:1139-1151.
5. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, HealeyJS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fi brillation: An analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
6. Kaiser C. Pradaxa bleeding deaths raise concern. MedPage Today 2011 Nov 2. Available at http://www.medpagetoday.com/Cardiology/ Strokes/29411. Accessed 2011 Nov 4.
7. Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. N Schmied Arch Pharmacol 2005; 371:195-201. (Pubitemid 40768411)
8. Schwarz U, Gramatte T, Krappweis T, Oertel R, Kirch W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 2000; 38:161-167. (Pubitemid 30193611)
9. van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of direct thrombin inhibitor Dabigatran, by recombinant factor VIIa ore activated prothrombin complex concentrations. Haematologica 2008; 93:148-0370.
10. Van Ryn J, Stangier J, Haertter S. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127.